285 related articles for article (PubMed ID: 37508575)
1. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking Back and Forward.
Okła K
Cells; 2023 Jul; 12(14):. PubMed ID: 37508575
[TBL] [Abstract][Full Text] [Related]
2. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
Front Immunol; 2019; 10():691. PubMed ID: 31001284
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
4. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
5. Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils.
Khan ANH; Emmons TR; Wong JT; Alqassim E; Singel KL; Mark J; Smith BE; Tario JD; Eng KH; Moysich KB; Odunsi K; Abrams SI; Segal BH
Cancer Immunol Res; 2020 Jun; 8(6):819-828. PubMed ID: 32238380
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells-new and exciting players in lung cancer.
Yang Z; Guo J; Weng L; Tang W; Jin S; Ma W
J Hematol Oncol; 2020 Jan; 13(1):10. PubMed ID: 32005273
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Krishnamoorthy M; Gerhardt L; Maleki Vareki S
Cells; 2021 May; 10(5):. PubMed ID: 34065010
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges.
Okła K; Wertel I; Polak G; Surówka J; Wawruszak A; Kotarski J
Int Rev Immunol; 2016 Sep; 35(5):372-385. PubMed ID: 27644763
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
11. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
12. A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward.
Stenzel AE; Abrams SI; Moysich KB
Front Immunol; 2019; 10():1608. PubMed ID: 31354741
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells in obstetrical and gynecological diseases.
Zheng ZM; Yang HL; Lai ZZ; Wang CJ; Yang SL; Li MQ; Shao J
Am J Reprod Immunol; 2020 Aug; 84(2):e13266. PubMed ID: 32418253
[TBL] [Abstract][Full Text] [Related]
14. Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.
Mabuchi S; Sasano T; Komura N
Cells; 2021 Feb; 10(2):. PubMed ID: 33562495
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.
Koinis F; Xagara A; Chantzara E; Leontopoulou V; Aidarinis C; Kotsakis A
Cells; 2021 Dec; 11(1):. PubMed ID: 35011582
[TBL] [Abstract][Full Text] [Related]
16. The Role of Myeloid-Derived Suppressor Cells (MDSCs) in the Development and/or Progression of Endometriosis-State of the Art.
Suszczyk D; Skiba W; Jakubowicz-Gil J; Kotarski J; Wertel I
Cells; 2021 Mar; 10(3):. PubMed ID: 33803806
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.
He JY; Huo FY; Tang HC; Liu B; Bu LL
Int Rev Cell Mol Biol; 2023; 375():33-92. PubMed ID: 36967154
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis.
Safarzadeh E; Orangi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2018 Apr; 233(4):3024-3036. PubMed ID: 28661031
[TBL] [Abstract][Full Text] [Related]
20. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
